Home
>
Our Solutions

Nonclinical

IND

Early Phase

Phase II-III

NDA/BLA

Post-Market
Early Clinical Development
Our independent central laboratory and GLP compliant biological analysis laboratory collaborate with quantitative pharmacology and clinical development teams to provide scientific clinical development strategies and plans, helping your project smoothly progress from preclinical to clinical.
- Drug safety assessment: Preliminary understanding of the safety of drugs in the human body, including possible side effects, adverse reactions, etc
- Optimal drug dosage: Through small-scale experiments, explore the effective dosage range of drugs in the human body, and provide reference for subsequent clinical trials
- Precision dosing regimen: Study the absorption, distribution, metabolism, and excretion processes of drugs in the human body, providing a basis for developing dosing regimens

Pivotal Trial
- Expertise across diverse therapeutic areas, including oncology, neurology, endocrinology, hepatology, pediatrics, and more.
- Client-tailored clinical trial solutions to meet your product's specific needs.
- A globally compliant quality management system and robust SOP framework ensure dynamic monitoring and efficient management of the entire clinical project lifecycle, delivering high-quality results on time and within budget.

Post-Marketing Research
Services include Phase IV trials, re-registration, traditional Chinese medicine registration, post- marketing safety studies, adverse event monitoring, real-world studies (RWS), investigator-initiated trials (IIT), and more.

Get in touch with SDM experts for your questions or comments and a member of our team will get back to you directly.
Let's Start a Conversation